Harvard Bioscience, Inc. (NASDAQ:HBIO) is reporting third quarter financial results on Thursday 5th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, HBIO is expected to report 3Q20 income of $ 0.03 per share from revenue of $ 24.05 million.
For the full year, analysts anticipate top line of $ 99.56 million, while looking forward to income of $ 0.14 per share bottom line.
Previous Quarter Performance
Harvard Bioscience, Inc. revealed income for the second quarter of $ 0.05 per share, from the revenue of $ 23.31 million. The quarterly earnings improved 25.00 percent while revenues declined 21.20 percent compared with the same quarter last year.
According to street consensus, HBIO was expected to report 2Q20 loss of $ 0.03 per share from revenue of $ 22.19 million. The bottom line results beat street analysts by $ 0.08 or 266.67 percent, at the same time, top line results outshined analysts by $ 1.12 million or 5.05 percent.
Stock Performance
Shares of Harvard Bioscience, Inc. traded low $ -0.03 or -0.80 percent on Wednesday, reaching $ 3.70 with volume of 67.20 thousand shares. Harvard Bioscience, Inc. has traded high as $ 3.75 and has cracked $ 3.67 on the downward trend
The closing price of $ 3.70, representing a 168.35 % increase from the 52 week low of $ 1.39 and a 15.42 % decrease over the 52 week high of $ 4.41.
The company has a market capital of $ 144.09 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
Harvard Bioscience, Inc. will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.harvardbioscience.com
Harvard Bioscience, Inc. provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.
